These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10493286)

  • 1. Evaluation of a workplace hemochromatosis screening program.
    Stave GM; Mignogna JJ; Powell GS; Hunt CM
    Am J Prev Med; 1999 May; 16(4):303-6. PubMed ID: 10493286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemochromatosis detection in a health screening program at an Alabama forest products mill.
    Barton JC; Cheatwood SM; Key TJ; Acton RT
    J Occup Environ Med; 2002 Aug; 44(8):745-51. PubMed ID: 12185795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany.
    Niederau C; Niederau CM; Lange S; Littauer A; Abdel-Jalil N; Maurer M; Häussinger D; Strohmeyer G
    Ann Intern Med; 1998 Mar; 128(5):337-45. PubMed ID: 9490593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri.
    McDonnell SM; Hover A; Gloe D; Ou CY; Cogswell ME; Grummer-Strawn L
    Am J Med; 1999 Jul; 107(1):30-7. PubMed ID: 10403350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for hereditary hemochromatosis.
    Phatak PD; Guzman G; Woll JE; Robeson A; Phelps CE
    Arch Intern Med; 1994 Apr; 154(7):769-76. PubMed ID: 8147681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.
    Asberg A; Hveem K; Thorstensen K; Ellekjter E; Kannelønning K; Fjøsne U; Halvorsen TB; Smethurst HB; Sagen E; Bjerve KS
    Scand J Gastroenterol; 2001 Oct; 36(10):1108-15. PubMed ID: 11589387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why do people choose not to have screening for hemochromatosis?
    Wolthuizen M; Nisselle A; Halliday J; Metcalfe SA; Aitken M; Allen KJ; Delatycki MB
    Genet Test Mol Biomarkers; 2013 Jan; 17(1):21-4. PubMed ID: 23098241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database.
    Adams PC; Gregor JC; Kertesz AE; Valberg LS
    Gastroenterology; 1995 Jul; 109(1):177-88. PubMed ID: 7797016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A workplace breast cancer screening program. Costs and components.
    Schrammel P; Griffiths RI; Griffiths CB
    AAOHN J; 1998 Nov; 46(11):523-9. PubMed ID: 9934000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older.
    Baer DM; Simons JL; Staples RL; Rumore GJ; Morton CJ
    Am J Med; 1995 May; 98(5):464-8. PubMed ID: 7733125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of population-based screening for phenotypic hemochromatosis in young men.
    Asberg A; Tretli S; Hveem K; Bjerve KS
    Scand J Gastroenterol; 2002 Oct; 37(10):1212-9. PubMed ID: 12408528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we screen for hemochromatosis? An examination of evidence of downstream effects on morbidity and mortality.
    Mainous AG; Gill JM; Pearson WS
    Arch Intern Med; 2002 Aug 12-26; 162(15):1769-74. PubMed ID: 12153381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.
    Balan V; Baldus W; Fairbanks V; Michels V; Burritt M; Klee G
    Gastroenterology; 1994 Aug; 107(2):453-9. PubMed ID: 8039622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors.
    Adams PC; Kertesz AE; McLaren CE; Barr R; Bamford A; Chakrabarti S
    Hepatology; 2000 May; 31(5):1160-4. PubMed ID: 10796893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers.
    Bassett ML; Leggett BA; Halliday JW; Webb S; Powell LW
    J Hepatol; 1997 Sep; 27(3):517-24. PubMed ID: 9314130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia.
    de Graaff B; Neil A; Si L; Yee KC; Sanderson K; Gurrin L; Palmer AJ
    Appl Health Econ Health Policy; 2017 Aug; 15(4):521-534. PubMed ID: 28035629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease.
    Bonkovsky HL; Slaker DP; Bills EB; Wolf DC
    Gastroenterology; 1990 Oct; 99(4):1079-91. PubMed ID: 2394329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis.
    Buffone GJ; Beck JR
    Clin Chem; 1994 Aug; 40(8):1631-6. PubMed ID: 8045021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary hemochromatosis.
    Crownover BK; Covey CJ
    Am Fam Physician; 2013 Feb; 87(3):183-90. PubMed ID: 23418762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness.
    Adams PC; Kertesz AE; Valberg LS
    Hepatology; 1995 Dec; 22(6):1720-7. PubMed ID: 7489980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.